All Stories

  1. Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of Ureaplasma parvum infection

    Article • Transplant Infectious Disease, February 2018, Wiley

    Emmanuel Katsanis

  2. Pak2 regulates myeloid-derived suppressor cell development in mice

    Article • Blood Advances, October 2017, American Society of Hematology

    Emmanuel Katsanis

  3. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation

    Article • Bone Marrow Transplantation, September 2017, Nature

    Emmanuel Katsanis

  4. Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events

    Article • Case Reports in Hematology, January 2017, Hindawi Publishing Corporation

    Emmanuel Katsanis

  5. Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies

    Article • Journal of Pediatric Hematology/Oncology, November 2016, Wolters Kluwer Health

    Emmanuel Katsanis

  6. Post-transplant bendamustine reduces GvHD while preserving GvL in haploidentical BMT

    Article • British Journal of Haematology, March 2016, Wiley

    Emmanuel Katsanis, Yi Zeng

  7. Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia

    Article • Annals of Hematology, January 2016, Springer Science + Business Media

    Emmanuel Katsanis

  8. Targeted immunotherapy for pediatric solid tumors

    Article • OncoImmunology, August 2015, Taylor & Francis

    Emmanuel Katsanis

  9. Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant

    Article • Journal of Adolescent and Young Adult Oncology, March 2015, Mary Ann Liebert Inc

    Emmanuel Katsanis

  10. Endoplasmic Reticulum Chaperones and Their Roles in the Immunogenicity of Cancer Vaccines

    Article • Frontiers in Oncology, January 2015, Frontiers

    Emmanuel Katsanis

  11. T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1

    Article • BioMed Research International, January 2015, Hindawi Publishing Corporation

    Philippe SAAS, Emmanuel Katsanis

  12. Immunotherapy for Pediatric Solid Tumors

    Article • January 2015, Springer Science + Business Media

    Emmanuel Katsanis

  13. Neuroblastoma☆

    Article • January 2015, Elsevier

    Emmanuel Katsanis

  14. Abstract 150: Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Emmanuel Katsanis

  15. Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy

    Article • Pediatric Blood & Cancer, August 2014, Wiley

    Emmanuel Katsanis

  16. Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue

    Article • Journal of Pediatric Hematology/Oncology, July 2014, Wolters Kluwer Health

    Emmanuel Katsanis

  17. PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15

    Article • European Journal of Immunology, May 2014, Wiley

    Emmanuel Katsanis

  18. Chemotherapeutic targeting of myeloid-derived suppressor cells

    Article • OncoImmunology, January 2014, Taylor & Francis

    Emmanuel Katsanis

  19. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

    Article • International Journal of Hyperthermia, June 2013, Taylor & Francis

    Emmanuel Katsanis

  20. The ‘peptidome’ of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity

    Article • International Journal of Hyperthermia, May 2013, Taylor & Francis

    Emmanuel Katsanis

  21. Abstract 4740: Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Emmanuel Katsanis

  22. Dendritic Cells for Cancer Immunotherapy

    Article • January 2013, Springer Science + Business Media

    Emmanuel Katsanis

  23. Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy

    Article • Critical Reviews in Immunology, January 2013, Begell House

    Emmanuel Katsanis

  24. The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer

    Article • Developmental Immunology, January 2013, Hindawi Publishing Corporation

    Emmanuel Katsanis

  25. Diagnostic and Treatment Challenges for the Pediatric Hematologist Oncologist in Endemic Areas for Coccidioidomycosis

    Article • Journal of Pediatric Hematology/Oncology, July 2012, Wolters Kluwer Health

    Emmanuel Katsanis

  26. Late Effects in Adult Survivors of Pediatric Cancer: A Guide for the Primary Care Physician

    Article • The American Journal of Medicine, July 2012, Elsevier

    Emmanuel Katsanis

  27. Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells

    Article • OncoImmunology, July 2012, Taylor & Francis

    Emmanuel Katsanis

  28. The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance

    Article • Developmental Immunology, January 2011, Hindawi Publishing Corporation

    Emmanuel Katsanis

  29. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells

    Article • Immunobiology, July 2010, Elsevier

    Emmanuel Katsanis

  30. Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells

    Article • The Journal of Immunology, January 2010, The American Association of Immunologists

    Emmanuel Katsanis

  31. Personalized dendritic cell-based tumor immunotherapy

    Article • Immunotherapy, January 2010, Future Medicine

    Emmanuel Katsanis

  32. Killer dendritic cells and their potential for cancer immunotherapy

    Article • Cancer Immunology Immunotherapy, July 2009, Springer Science + Business Media

    Emmanuel Katsanis

  33. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens

    Article • International Journal of Hyperthermia, January 2008, Taylor & Francis

    Emmanuel Katsanis

  34. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia

    Article • The FASEB Journal, July 2007, Federation of American Societies For Experimental Biology (FASEB)

    Emmanuel Katsanis

  35. The inhibition of TNF-α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model

    Article • Experimental Cell Research, July 2007, Elsevier

    Emmanuel Katsanis

  36. CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease

    Article • Clinical Immunology, April 2007, Elsevier

    Emmanuel Katsanis

  37. Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading

    Article • APOPTOSIS, May 2006, Springer Science + Business Media

    Emmanuel Katsanis

  38. Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10

    Article • Cancer Immunology Immunotherapy, April 2006, Springer Science + Business Media

    Emmanuel Katsanis

  39. Peritransplantation Vaccination with Chaperone-Rich Cell Lysate Induces Antileukemia Immunity

    Article • Biology of Blood and Marrow Transplantation, March 2006, Elsevier

    Emmanuel Katsanis

  40. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination

    Article • International Journal of Cancer, January 2006, Wiley

    Emmanuel Katsanis

  41. Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines

    Article • Cancer Immunology Immunotherapy, July 2005, Springer Science + Business Media

    Emmanuel Katsanis

  42. Chaperone-rich cell lysates, immune activation and tumor vaccination

    Article • Cancer Immunology Immunotherapy, May 2005, Springer Science + Business Media

    Emmanuel Katsanis

  43. Cargo from Tumor-Expressed Albumin Inhibits T-Cell Activation and Responses

    Article • Cancer Research, November 2004, American Association for Cancer Research (AACR)

    Emmanuel Katsanis

  44. Human Ovarian Tumor-Derived Chaperone-Rich Cell Lysates Activate Dentdritic Cells and Elicit T Cell Responses In Vitro

    Article • Journal of Immunotherapy, November 2004, Wolters Kluwer Health

    Emmanuel Katsanis

  45. Chaperone Proteins/Heat Shock Proteins As Anticancer Vaccines

    Article • January 2004, Springer Science + Business Media

    Emmanuel Katsanis

  46. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treatbcr-abl+ murine leukemia

    Article • International Journal of Cancer, January 2004, Wiley

    Emmanuel Katsanis

  47. Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway

    Article • Journal of Biomedicine and Biotechnology, January 2004, Hindawi Publishing Corporation

    Emmanuel Katsanis

  48. Neuroblastoma

    Article • January 2002, Elsevier

    Emmanuel Katsanis

  49. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl -positive leukemia in mice

    Article • Cancer Immunology Immunotherapy, March 2001, Springer Science + Business Media

    Emmanuel Katsanis

  50. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines

    Article • Cancer Immunology Immunotherapy, November 2000, Springer Science + Business Media

    Emmanuel Katsanis

  51. Invasion and metastasis of a mammary tumor involves TGF-? signaling

    Article • International Journal of Cancer, January 2000, Wiley

    Emmanuel Katsanis

  52. Nebulized Interleukin 2 Liposomes: Aerosol Characteristics and Biodistribution

    Article • Journal of Pharmacy and Pharmacology, October 1997, Wiley

    Emmanuel Katsanis

  53. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases

    Article • Cancer, April 1997, Wiley

    Emmanuel Katsanis

  54. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia

    Article • British Journal of Haematology, March 1997, Wiley

    Emmanuel Katsanis

  55. Improved Immunostimulatory Function of Bone Marrow Derived Macrophages Transduced with the Granulocyte-Macrophage Colony Stimulating Factor Gene

    Article • Cancer Biotherapy & Radiopharmaceuticals, February 1997, Mary Ann Liebert Inc

    Emmanuel Katsanis

  56. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: A novel antitumor agent?

    Article • Journal of Pediatric Surgery, February 1997, Elsevier

    Emmanuel Katsanis

  57. IL-15 ADMINISTRATION FOLLOWING SYNGENEIC BONE MARROW TRANSPLANTATION PROLONGS SURVIVAL OF LYMPHOMA BEARING MICE1

    Article • Transplantation, September 1996, Wolters Kluwer Health

    Emmanuel Katsanis

  58. Interleukin-2 Secretion by Transduced and Unselected BDL-2 Lymphoma Results in Increased Survival in Mice with Previously Established Disseminated Disease

    Article • Cancer Biotherapy & Radiopharmaceuticals, April 1996, Mary Ann Liebert Inc

    Emmanuel Katsanis

  59. Effective Immunization Against Neuroblastoma Using Double-Transduced Tumor Cells Secreting GM-CSF and Interferon-γ

    Article • Journal of Immunotherapy, March 1996, Wolters Kluwer Health

    Emmanuel Katsanis

  60. Infusions of interleukin-1? after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity

    Article • Journal of Clinical Immunology, May 1994, Springer Science + Business Media

    Emmanuel Katsanis

  61. Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response

    Article • Journal of Pediatric Surgery, April 1994, Elsevier

    Emmanuel Katsanis

  62. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing

    Article • Cancer Immunology Immunotherapy, March 1994, Springer Science + Business Media

    Emmanuel Katsanis

  63. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing

    Article • Cancer Immunology Immunotherapy, February 1994, Springer Science + Business Media

    Emmanuel Katsanis

  64. Interleukin-2 Gene Transfer into Murine Neuroblastoma Decreases Tumorigenicity and Enhances Systemic Immunity Causing Regression of Preestablished Retroperitoneal Tumors

    Article • Journal of Immunotherapy, February 1994, Wolters Kluwer Health

    Emmanuel Katsanis

  65. Depot Characteristics and Biodistribution of Interleukin-2 Liposomes, Importance of Route of Administration

    Article • Journal of Immunotherapy, July 1992, Wolters Kluwer Health

    Emmanuel Katsanis

  66. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis

    Article • Cancer Immunology Immunotherapy, March 1991, Springer Science + Business Media

    Emmanuel Katsanis

  67. Influenza in children with cancer

    Article • The Journal of Pediatrics, July 1989, Elsevier

    Emmanuel Katsanis

  68. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis

    Article • The Journal of Pediatrics, July 1988, Elsevier

    Emmanuel Katsanis

  69. Systemic lupus erythematosus and sickle hemoglobinopathies: A report of two cases and review of the literature

    Article • American Journal of Hematology, June 1987, Wiley

    Emmanuel Katsanis

  70. Wegener granulomatosis

    Article • The Journal of Pediatrics, May 1986, Elsevier

    Emmanuel Katsanis